Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Oragenics Inc.

    AMEX: OGEN · Real-Time Price · USD
    0.18
    0.00 (0.00%)
    At close: May 09, 2025, 10:16 AM
    0.00%
    Bid 0.18
    Market Cap 3.93M
    Revenue (ttm) n/a
    Net Income (ttm) -10.57M
    EPS (ttm) -1.6
    PE Ratio (ttm) -0.11
    Forward PE -0.49
    Analyst n/a
    Ask 0.19
    Volume 33,934
    Avg. Volume (20D) 496,604
    Open 0.19
    Previous Close 0.18
    Day's Range 0.18 - 0.19
    52-Week Range 0.16 - 3.43
    Beta 1.16

    About OGEN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol OGEN
    Website n/a
    Full Company Profile

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    7 months ago
    +6.39%
    Oragenics shares are trading higher after the comp... Unlock content with Pro Subscription
    8 months ago
    -46.2%
    Oragenics shares are trading lower after the company announced $4.45 million public offering of 8,106,584 shares at $0.55 per share.
    news image

    1 year ago · businesswire.com

    Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

    SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...

    news image

    1 year ago · businesswire.com

    Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

    SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...

    news image

    1 year ago · businesswire.com

    Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

    SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...

    Add to Watchlist